We are a unique partnership of investment talent and best-in-class commercial scientists
whose technologies are today valued in excess of $100BN combined.
Founding & Managing Partner
Alice has over a decade of investing experience, including at TPG Capital (leading global private equity firm with >$70BN AUM) and Lansdowne Partners (leading investment firm with >$15BN AUM). Her predominant investing focus has been in tech and disruptive healthcare.
Alice holds a Double First-Class degree in Mathematics, and Master’s in Mathematics/Physics from the University of Cambridge. She was a Fulbright Scholar and a Baker Scholar at Harvard Business School.
Andy is a CERN leader and Head of the Cavendish Laboratory (Physics Department) at the University of Cambridge.
Andy is a Professor of High Energy Physics at the University of Cambridge and Head of the Physics Department. He is an expert in high energy physics, extraspace dimensions, quantum-sized black holes and supersymmetry, with over 500 publications to his name. He is a founder of the ATLAS experiment for the Large Hadron Collider and has commercially developed silicon detectors, fast electronics, large software systems and pattern recognition, and he has pioneered computational radiotherapy and artificial photosynthesis. Andy’s awards include the Pilkington Prize for excellence.
David is Co-President of Clayton Dubilier & Rice, where he has worked for 23 years and is a member of the Investment Committee. Based in London, he is responsible for the Firm’s European business. He is personally responsible for investments in B&M Retail, BCA, Belron, BUT, Kalle Group, Mauser Group, Motor Fuel Group, and Westbury Street Holdings, and played a key role in many others. Previously, David worked in the private equity and investment banking divisions of Morgan Stanley.
David holds a BA in Economics from Amherst College and is a graduate of Harvard Business School.
Sir Gregory is a Nobel Laureate, inventor of the technology leading to Humira (c.$20BN revenue in 2018, the world’s greatest grossing drug) and founder of three companies. He is a former Master of Trinity College, University of Cambridge.
Sir Gregory is the inventor of the technology that led to Humira (Adalimumab), the first fully human antibody blockbuster and the best-selling drug worldwide. He was awarded the 2018 Nobel Prize for his pioneering work in using phage display for the directed evolution of antibodies, with the aim of producing new therapeutics. Sir Gregory’s development of technologies for making pharmaceutical antibodies by genetic engineering have led to many of the world’s top-selling pharmaceutical treatments for cancer and immune disorders, also including the “humanised” antibodies Herceptin (for treatment of breast cancer) and Lucentis (for treatment of wet acute macular degeneration). In order to see his technologies applied, Sir Gregory founded several successful start-up companies.
Sir Gregory was knighted for his services to Molecular Biology in 2004 and his other awards include a Royal Medal in 2011 and the Nobel Prize for Chemistry in 2018. Sir Gregory is a Fellow of the Royal Society.
Senior Investment Associate
Joanna joined Ahren from the Boston Consulting Group (BCG), where she worked on strategic projects across a range of industries including healthcare, insurance and the public sector.
Joanna holds a PhD in fetal immunology, focusing on childhood leukaemia, and a First-Class Master’s and undergraduate degree from the University of Oxford.
John is Head of the Artificial Intelligence Group at the University of Cambridge and inventor of IRIS (eye) recognition technology used to register 1.5BN citizens worldwide.
John’s areas of expertise include computer vision, information theory, neuro computing and statistical pattern recognition. He was appointed OBE in 1999. His awards include the Information Technology Award and Medal of the British Computer Society, the “Time 100” Innovators Award and he has been inducted into the US National Inventors Hall of Fame. He is a Fellow of the Royal Academy of Engineering, the US National Academy of Inventors, the Institute of Mathematics and its Applications, the International Association for Pattern Recognition and the British Computer Society.
Lord Martin Rees is a world-renowned astrophysicist, Astronomer Royal, founder of CSER, former President of the Royal Society and former Master of Trinity College, University of Cambridge.
Lord Martin Rees is a world-leading cosmologist and astrophysicist. He has been Astronomer Royal since 1995 and was Master of Trinity College, Cambridge from 2004 to 2012 and President of the Royal Society between 2005 and 2010.
Lord Rees is the author of more than 500 research papers, and he has made important contributions to the origin of cosmic microwave background radiation, as well as to galaxy clustering and formation. His studies of the distribution of quasars led to final disproof of Steady State theory. In addition to his scientific interests, Lord Rees has written and spoken extensively about the interfaces between science, ethics and politics. He is a member of the Board of the Institute for Advanced Study in Princeton, the Oxford Martin School and the Gates Cambridge Trust. He co-founded the Centre for the Study of Existential Risk and serves on the Scientific Advisory Board for the Future of Life Institute.
Oliver joined Ahren with meaningful start-up experience, having previously worked for a spin-out company recognised by Nesta as the leading British diagnostic technology to combat antimicrobial resistance.
Oliver holds a First-Class undergraduate degree in Biochemistry from the University of Exeter.
Peter joined Ahren from Advent, where he has been a General Partner since 1999, following six years in the technology team at Schroder Ventures (nowPermira) in Paris.
Previously, he worked in software development with Picker International as well as in business and IT consulting with PricewaterhouseCoopers.
Peter has 15 years’ experience of investing in growing technology businesses, mainly focusing on growth equity investments. He has invested in a range of different sectors including software, internet, communications, and digital media businesses. He serves on the boards of several companies, including DailyMotion, Snell, OpenCloud and Amberfin and is a Non-Executive Director for Neverfail.
Peter holds a BSc from Imperial College, London and a MBA from INSEAD.
Peter joined Ahren from the healthcare investment banking coverage team at J.P.Morgan (top-ranked in the space in recent years) where he worked on a number of notable transactions advising a range of FTSE 100, private equity and growth clients on innovative and transformative transactions.
Peter holds a First-Class Master’s and undergraduate degree in Physics from the University of Cambridge. He majored in relativistic astrophysics, particle physics, biophysics, mathematical and computational biology.
Chief Financial Officer
Robert has over 25 years of experience in the financial services sector, offshore and onshore, covering all aspects of accountancy including private practice, auditing, investment banking and investment management.
Robert joined Ahren as full-time CFO after 7 years as CFO at ERIM LLP, a boutique investment management firm. Robert is a Fellow of the Association of Chartered Certified Accountants, having qualified in 1996.
Zoubin is a world leader in machine learning and was co-founder of Geometric Intelligence, sold to Uber in December 2016. Zoubin currently acts as Chief Scientist for Uber, where he runs their AI labs.
Zoubin is a Professor of Information Engineering and leader of the Machine Learning Group at the University of Cambridge. He was a founding Director of the Alan Turing Institute, the UK’s national institute for data science and a Director of the Leverhulme Centre for the Future of Intelligence. He was named in 2016 as one of the Top Ten Most Influential Scholars in Machine Learning. He has served as advisor to Microsoft, VocalIQ (acquired by Apple) and several other companies. He is a Fellow of the Royal Society.
Roberto is a Professor of Information Engineering at the University of Cambridge with expertise in computer vision and robotics. He has helped support several successful start-ups.
Roberto was awarded his D.Phil. (PhD) in Computer Vision from the University of Oxford and was a Toshiba Fellow and engineer at the Toshiba Corporation Research and Development Centre in Kawasaki, Japan. He joined the Department of Engineering, University of Cambridge in 1992 and is a Fellow of Jesus College. He is a Fellow of the Royal Academy of Engineering.
Roberto’s domains of expertise include the recovery of motion and 3D shape of visible surfaces from image sequences; object detection and recognition; novel man-machine interfaces using hand, face and body gestures; real-time visual tracking for localisation and robot guidance; applications of computer vision in mobile phones, visual inspection and image-retrieval and video search. He has authored 2 books, edited 12 volumes and co-authored more than 400 papers. Several of his students have spun out highly successful start-ups.
Sir Shankar is Founder of two companies and the principal inventor of the leading next generation human genome sequencing technology core to all Illumina sequencing platforms, estimated to be worth >$30BN.
Sir Shankar’s technology has made routine, accurate, low-cost sequencing of human genomes a reality, has revolutionised biology and accelerated the development of genomic personalised medicine.
Sir Shankar is the Herchel Smith Professor of Medicinal Chemistry at the University of Cambridge and Senior Group Leader at the Cancer Research UK Cambridge Institute. His awards include the Royal Medal (2018), the RoyalSociety Mullard Award (2009), The BBSRC Innovator of the year (2010) and the Tetrahedron Prize (2013). He is a Fellow of the Royal Society, the Academy of Medical Sciences and a member of EMBO.
Steve is the Originator of Olaparib/Lynparza, recently partnered by AstraZeneca with Merck and valued as an asset at up to $17BN, and used to treat 30,000 patients worldwide to date.
Steve is the University of Cambridge Frederick James Quick and Cancer Research UK Professor of Biology. He is also Head of Cancer Research UK Laboratories at the Wellcome Trust/Cancer Research UK Gurdon Institute. He is a leading expert in the field of DNA repair and DNA-damage signalling and invented Lynparza, the world’s first marketed DNA-repair enzyme inhibitor, an effective treatment of breast and other cancers.
Steve’s awards include the Heineken Prize for Science by the Royal Netherlands Academy of Arts and Science in 2016 and the UK GSN Medal for his contributions to the field of genome stability. He is a fellow of the Royal Society.
Sir Venki is a Nobel Laureate and President of the Royal Society, the UK’s premier science body.
Sir Venki received the 2009 Nobel Prize in Chemistry for his work that led to solving the atomic structure of the ribosome and has also worked on histone and chromatin structures, which help us to understand how DNA is organised in cells.
Sir Venki is a Group Leader at the MRC Laboratory of Molecular Biology in Cambridge. He was knighted in 2012 and his further awards include the Heatley Medal of the British Biochemical Society. He is a Member of the US National Academy of Sciences, Leopoldina and EMBO, and a Foreign Member of the Indian National Science Academy.
Robert is also the Chairman of UK Government Investments, which is responsible for corporate finance and corporate governance for HMG, and Chairman of the charity Royal Springboard. Robert was previously Chairman of Marks & Spencer (2010-2017). He is also a Director of the Investor Forum and a member of The Takeover Panel Appeal Board.
Robert is a Trustee of Teach First and a visiting Fellow at the Oxford University, Said Business School. He was a member of the Advisory Board of The Sutton Trust from 2014-17 and Chairman of Rugby School from 2009-2014. Until 2010, Robert spent over 30 years in investment banking with Schroders/Citigroup. He was formerly Vice-Chairman of Citi Europe and Chairman of Citi’s European Investment Bank.
Founding and Managing Partner
Senior Investment Associate
Chief Financial Officer
Chairman of the LPAC